Immune Mediated Autologous Cytotoxicity Against Hematopoietic Precursor Cells in Patients with Myelodysplastic Syndrome

Overview

Journal Haematologica

Specialty Hematology

Date 2009 Feb 21

PMID 19229054

Citations 28

Authors

Martine E D Chamuleau

Theresia M Westers

Linda van Dreunen

Judith Groenland

Adri Zevenbergen

Corien M Eeltink

Gert J Ossenkoppele

Arjan A van de Loosdrecht

Affiliations

Soon will be listed here.

Abstract

Background: An activated immune system has been observed in patients with myelodysplastic syndrome but its exact contribution to disease development and control is not fully clarified. On the one hand an activated and skewed T-cell repertoire has been reported, but on the other hand, decreased natural killer cell function has been found. Immune activation could reflect undesired autoimmune reactions against normal hematopoietic precursor cells as well as effective immune-surveillance against dysplastic clones.

Design And Methods: We have investigated immune effector cells (lymphocyte subsets, lymphocyte activation markers, and natural killer cells) of 40 low and intermediate risk myelodysplastic syndrome patients and compared them to those of 10 age-matched healthy donors. Furthermore, we have analyzed the cytotoxic capacity of effector cells against autologous bone marrow hematopoietic precursor cells of 8 myelodysplastic syndrome patients and 2 healthy donors.

Results: In myelodysplastic syndrome patients, we have found an activated state of lymphocytes, determined by increased percentages of effector T cells with cytotoxic profile, more skewing of the T-cell receptor Vbeta (TCR-Vbeta) repertoire, and decreased frequencies of regulatory T cells, when compared to healthy donors. The percentage of natural killer cells did not differ between myelodysplastic syndrome patients and healthy donors, but natural killer cells of myelodysplastic syndrome patients expressed increased levels of granzyme B. Finally, we have demonstrated non-MHC restricted autologous cytotoxicity up to 90% against aberrant hematopoietic precursor cells, presumably mediated by natural killer cells.

Conclusions: Our data point to a role for active immune-surveillance in myelodysplastic syndrome, as demonstrated by activated T cells and TCR-Vss skewing. Autologous cytotoxicity against hematopoietic precursor cells was natural killer cell dependent, which points to an additional role for the innate immune system in immune-surveillance of myelodysplastic syndrome patients.

Citing Articles

Low Levels of Natural Killer Cell in Newly Diagnosed Myelodysplastic Syndromes Patients May Confer Poor Prognosis: A Retrospective Cohort Study.

Gong S, Shi C Cancer Manag Res. 2024; 16:753-760.

PMID: 38974093 PMC: 11227877. DOI: 10.2147/CMAR.S469393.

Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.

Tentori C, Zhao L, Tinterri B, Strange K, Zoldan K, Dimopoulos K Hemasphere. 2024; 8(5):e64.

PMID: 38756352 PMC: 11096644. DOI: 10.1002/hem3.64.

Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cells.

van Spronsen M, Van Gassen S, Duetz C, Westers T, Saeys Y, van de Loosdrecht A Leukemia. 2024; 38(6):1365-1377.

PMID: 38459168 PMC: 11147773. DOI: 10.1038/s41375-024-02203-z.

The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome.

Zheng L, Zhang L, Guo Y, Xu X, Liu Z, Yan Z Front Immunol. 2022; 13:1078421.

PMID: 36569863 PMC: 9767949. DOI: 10.3389/fimmu.2022.1078421.

Past, present and future in low-risk myelodysplastic syndrome.

Toprak S Front Med (Lausanne). 2022; 9:967900.

PMID: 35911422 PMC: 9334722. DOI: 10.3389/fmed.2022.967900.

References

Corey S, Minden M, Barber D, Kantarjian H, Wang J, Schimmer A . Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007; 7(2):118-29. DOI: 10.1038/nrc2047. View

Kook H, Zeng W, Guibin C, Kirby M, Young N, Maciejewski J . Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol. 2001; 29(11):1270-7. DOI: 10.1016/s0301-472x(01)00736-6. View

Kochenderfer J, Kobayashi S, Wieder E, Su C, Molldrem J . Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood. 2002; 100(10):3639-45. DOI: 10.1182/blood-2002-01-0155. View

van de Loosdrecht A, Westers T, Westra A, Drager A, van der Velden V, Ossenkoppele G . Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2007; 111(3):1067-77. DOI: 10.1182/blood-2007-07-098764. View

Kiladjian J, Bourgeois E, Lobe I, Braun T, Visentin G, Bourhis J . Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia. 2006; 20(3):463-70. DOI: 10.1038/sj.leu.2404080. View

Ghiringhelli F, Apetoh L, Housseau F, Kroemer G, Zitvogel L . Links between innate and cognate tumor immunity. Curr Opin Immunol. 2007; 19(2):224-31. DOI: 10.1016/j.coi.2007.02.003. View

Epperson D, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett A . Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res. 2001; 25(12):1075-83. DOI: 10.1016/s0145-2126(01)00083-2. View

Costello R, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci M, Reviron D . Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood. 2002; 99(10):3661-7. DOI: 10.1182/blood.v99.10.3661. View

Epling-Burnette P, Bai F, Painter J, Rollison D, Salih H, Krusch M . Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007; 109(11):4816-24. PMC: 1885518. DOI: 10.1182/blood-2006-07-035519. View

10.

Trapani J, Smyth M . Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002; 2(10):735-47. DOI: 10.1038/nri911. View

11.

Broliden P, Dahl I, Hast R, Johansson B, Juvonen E, Kjeldsen L . Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica. 2006; 91(5):667-70. View

12.

Epling-Burnette P, Painter J, Rollison D, Ku E, Vendron D, Widen R . Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia. 2007; 21(4):659-67. DOI: 10.1038/sj.leu.2404590. View

13.

Meers S, Vandenberghe P, Boogaerts M, Verhoef G, Delforge M . The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: a single centre study of 131 patients. Leuk Res. 2007; 32(7):1026-35. DOI: 10.1016/j.leukres.2007.10.004. View

14.

Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88. View

15.

Kordasti S, Ingram W, Hayden J, Darling D, Barber L, Afzali B . CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood. 2007; 110(3):847-50. DOI: 10.1182/blood-2007-01-067546. View

16.

Westers T, Houtenbos I, Schuurhuis G, Ossenkoppele G, van de Loosdrecht A . Quantification of T-cell-mediated apoptosis in heterogeneous leukemia populations using four-color multiparameter flow cytometry. Cytometry A. 2005; 66(1):71-7. DOI: 10.1002/cyto.a.20146. View

17.

Molldrem J, Jiang Y, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett A . Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol. 1998; 102(5):1314-22. DOI: 10.1046/j.1365-2141.1998.00920.x. View

18.

Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H . Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol. 2003; 78(1):56-61. DOI: 10.1007/BF02983241. View

19.

Beyer M, Schultze J . Regulatory T cells in cancer. Blood. 2006; 108(3):804-11. DOI: 10.1182/blood-2006-02-002774. View

20.

Vardiman J, Lee Harris N, Brunning R . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100(7):2292-302. DOI: 10.1182/blood-2002-04-1199. View